Piero Dalerba, M.D. | Center for Discovery and Innovation NJ   

Dalerba Lab

Piero Dalerba, M.D., is an associate member of the Center for Discovery and Innovation.

Dr. Dalerba and his team focus on the discovery of biomarkers that are predictive of tumor response to anti-neoplastic drugs, in order to improve therapeutic guidelines and decision-making algorithms for cancer patients. Dr. Dalerba's team uses single-cell technologies (e.g., FACS, single-cell RNA-sequencing) to deconvolute the cell composition of malignant tissues and identify anti-tumor drugs that have selective activity against specific subtypes of cancer cells.

Dr. Dalerba brought his research to the CDI in 2024. His prior appointments were as Assistant Professor of Pathology and Cell Biology at Columbia University, and as Instructor of Medicine at Stanford University. He earned his medical degree (MD) from the University of Milan (Italy) in 1995, and has received a series of distinctions over his career including: the 9th International PBI Valentina Lana Prize in Molecular Immunology (2002), a BD Biosciences Stem Cell Research Grant (2011), a National Comprehensive Cancer Network (NCCN) Young Investigator Award (2012), a Runyon-Rachleff Innovation Award from the Damon Runyon Cancer Research Foundation (2016), a Schaefer Research Scholarship from Columbia University (2017), a Breast Cancer Alliance (BCA) Young Investigator Grant (2018), a Kara Gelb Memorial Grant (2018) from the Adenoid Cystic Carcinoma Research Foundation (ACCRF), a VELOCITY Fellow Grant Award from the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University (2019), and a Columbia Stem Cell Initiative (CSCI) Seed Fund Award (2022), among other awards and grants."

Selected Publications

Piero Dalerba, Scott J Dylla, In-Kyung Park 2007| Phenotypic characterization of human colorectal cancer stem cells. PNAS 2007 Jun 12;104(24):10158-63. Pubmed Link

Piero Dalerba, Tomer Kalisky, Debashis Sahoo. 2011 | Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol. 2011 Nov 13;29(12):1120-7. Pubmed Link

William J Raab, Arabella Mazzocchi, Paolo Radice. 2022 | A Microsatellite in the Coding Sequence of HLA-A/B Is a Mutation Hotspot in Colon Cancer With Microsatellite Instability. Gastroenterology. 2022 Mar;162(3):960-963.e3. Pubmed Link

Sara Viragova, Luis Aparicio, Pierangela Palmerini. 2023 | Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. J Natl Cancer Inst. 2023 Jul 6;115(7):838-852. Pubmed Link

Reviews and Editorials

Estimating the Economic Value of CDX2 as a Predictive Biomarker to Guide Treatment Decisions in Stage II Colon Cancer

The Dynamic Identity of Intestinal Cancer Stem Cells

Cancer stem cells and tumor metastasis: first steps into uncharted territory

Cancer stem cells: models and concepts

For a complete list of publications, please visit PubMed.gov

Contact the Lab

Email: Piero.Dalerba@hmh-cdi.org

Mailing Address:
Center for Discovery and Innovation
111 Ideation Way
Nutley, NJ 07110

Google Scholar

We use cookies to improve your site experience. By using this site,
you agree to our Terms & Conditions. Also, please read our Privacy Policy. Accept All CookiesLearn More